NASDAQ:LEXXW Lexaria Bioscience (LEXXW) Stock Price, News & Analysis $0.12 -0.03 (-20.26%) As of 08/21/2025 03:05 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Lexaria Bioscience Stock (NASDAQ:LEXXW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lexaria Bioscience alerts:Sign Up Key Stats Today's Range$0.12▼$0.1250-Day Range$0.08▼$0.2252-Week Range$0.07▼$1.51Volume586 shsAverage Volume8,882 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. Read More Receive LEXXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address LEXXW Stock News HeadlinesLexaria Bioscience Earnings Analysis: Q1 RecapJanuary 10, 2025 | benzinga.comLexaria Bioscience finalizes clinical study agreementDecember 20, 2024 | uk.investing.comElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.August 22 at 2:00 AM | Paradigm Press (Ad)LEXX: Phase I Start ImminentDecember 5, 2024 | msn.comLexaria Bioscience Corp.: Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as ScheduledNovember 27, 2024 | finanznachrichten.deLexaria Bioscience’s DehydraTECH Outshines in Diabetes StudyNovember 21, 2024 | markets.businessinsider.comLexaria Bioscience Corp.: Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesOctober 17, 2024 | finanznachrichten.deLexaria Bioscience (NASDAQ:LEXX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comSee More Headlines LEXXW Stock Analysis - Frequently Asked Questions How have LEXXW shares performed this year? Lexaria Bioscience's stock was trading at $0.7641 on January 1st, 2025. Since then, LEXXW shares have decreased by 84.7% and is now trading at $0.1169. How do I buy shares of Lexaria Bioscience? Shares of LEXXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LEXXW CIK1348362 WebN/A Phone250-765-6424FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$615.92 thousand Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:LEXXW) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.